Prasugrel is a platelet inhibitor developed by Daiichi Sankyo Co. and produced by Ube and currently marketed in the United States in cooperation with Eli Lilly and Company for astute coronary syndromes planned for percutaneous coronary action (PCI). Prasugrel was accustomed for use in Europe in February 2009, and is currently accessible in the UK. On July 10, 2009, the US Food and Drug Administration accustomed the use of prasugrel for the abridgement of thrombotic cardiovascular contest (including stent thrombosis) in patients with astute coronary affection who are to be managed with PCI.
No comments:
Post a Comment